AI Diagnostic Ecosystems and Second-Opinion Dependency Risks

1. Introduction

AI diagnostic ecosystems increasingly operate as integrated healthcare platforms rather than isolated diagnostic tools. A single ecosystem may combine:

• AI imaging or pathology interpretation;
• electronic health records;
• patient-history databases;
• laboratory and genomic data;
• clinical decision-support software;
• physician referral networks;
• telemedicine;
• hospital information systems;
• insurance and reimbursement interfaces;
• specialist and second-opinion services; and
• proprietary APIs and interoperability layers.

The competition-law concern arises when an AI diagnostic provider becomes an important gateway between patients, primary physicians, specialists, hospitals and competing diagnostic providers.

A particularly important risk is second-opinion dependency. If the first AI system becomes sufficiently entrenched, competing diagnostic or specialist services may depend upon access to its patient data, diagnostic records, APIs, referral channels, validation infrastructure or physician network. The dominant ecosystem may then make independent second opinions technically, commercially or practically difficult.

This does not mean that every integrated AI diagnostic system is anticompetitive. Integration can produce legitimate benefits such as faster diagnosis, better interoperability, reduced duplication and improved clinical coordination. Competition law generally becomes relevant where market power is combined with exclusionary conduct, foreclosure, tying, discriminatory access, restrictive interoperability, or acquisition of important competitive alternatives.

2. Meaning of an AI Diagnostic Ecosystem

An AI diagnostic ecosystem can be represented as:

Patient → Data Collection → AI Diagnostic Engine → Clinical Recommendation → Physician → Specialist/Second Opinion → Treatment

Around this core may sit:

EHR + Imaging + Laboratory Data + Genomic Data + Cloud Infrastructure + Hospital Network + Insurance + Referral Platform + API

The ecosystem becomes competitively significant when one undertaking controls several of these layers simultaneously.

For example:

AI diagnostic platform → controls diagnostic model → controls patient data → controls referral interface → controls specialist network → controls access to second opinions.

The competitive concern is not merely the accuracy of the AI model. It is the possibility that control over one layer is leveraged into control over adjacent healthcare markets.

3. What Is “Second-Opinion Dependency”?

Second-opinion dependency exists where patients, doctors or competing providers cannot realistically obtain an independent alternative assessment without using infrastructure controlled by the first diagnostic ecosystem.

There are several forms.

A. Data dependency

A competing diagnostic provider may need access to:

• imaging files;
• longitudinal patient records;
• previous AI assessments;
• laboratory results;
• structured diagnostic metadata.

If the incumbent refuses interoperability, the competitor may be unable to provide a meaningful second opinion.

B. Referral dependency

An AI platform may become the principal source of referrals.

If physicians receive recommendations through the platform and the platform preferentially routes patients to affiliated specialists, competing specialists may lose access to patients.

C. API dependency

A diagnostic ecosystem may control an API through which hospitals and third-party diagnostic applications obtain patient information.

Restriction of that API can raise rivals' costs or prevent them from competing effectively.

D. Validation dependency

New diagnostic AI systems frequently require access to:

• clinical datasets;
• benchmarking systems;
• validation environments;
• specialist feedback;
• hospital testing infrastructure.

A dominant incumbent controlling these resources may make entry more difficult.

E. Workflow dependency

Once hospitals integrate one AI system into their clinical workflow, switching may become costly because physicians have adapted to:

• its interface;
• diagnostic terminology;
• reporting formats;
• electronic records;
• referral mechanisms;
• billing systems.

This can produce technological lock-in even where competing AI models are technically available.

4. Principal Competition-Law Issues

A. Market Definition

Several relevant markets may exist simultaneously.

Possible relevant markets

1. AI-assisted diagnostic software;
2. AI radiology interpretation;
3. AI pathology;
4. clinical decision-support systems;
5. digital diagnostic platforms;
6. specialist referral platforms;
7. second-opinion services;
8. healthcare data-access services;
9. interoperability/API services; and
10. hospital or physician services.

A central question is whether the AI product is merely a component of a competitive healthcare market or whether it constitutes a distinct platform through which competitors must operate.

5. Essential-Facility and Refusal-to-Deal Issues

Suppose an AI diagnostic platform possesses a uniquely important database containing millions of annotated medical images.

A rival asks for access.

The dominant platform refuses.

The rival consequently cannot provide an effective competing diagnostic service.

This may raise a refusal-to-deal/essential-facility issue.

However, competition law generally imposes a high threshold before a dominant undertaking is required to share proprietary infrastructure.

Relevant questions include:

• Is the input genuinely indispensable?
• Are realistic alternatives available?
• Can competitors reproduce the input?
• Is duplication technically or economically feasible?
• Would refusal eliminate effective competition?
• Is there an objective justification?
• Would access undermine privacy or cybersecurity?
• Can access be provided without compromising legitimate intellectual-property interests?

6. Data as a Competitive Bottleneck

AI diagnostic systems depend heavily upon data.

The competitive importance of data can arise from:

Volume + Variety + Velocity + Clinical quality + Annotation + Longitudinal history

An ecosystem possessing unique combinations of these characteristics may obtain an advantage over smaller competitors.

The Google/Fitbit merger is particularly relevant by analogy. The European Commission examined whether combining health-related data could affect digital healthcare competition and specifically considered potential foreclosure through access to Fitbit's Web API. The Commission recognized that restricting access could affect healthcare players and startups, although it ultimately did not conclude that the transaction would significantly impede competition in digital healthcare.

The important lesson is that data access and interoperability can be competition parameters even where the underlying product is not itself a traditional healthcare service.

7. Tying and Bundling

An AI diagnostic company may have substantial power in one market and use that power to force customers to purchase another service.

For example:

AI diagnostic software + mandatory affiliated second-opinion service

or:

AI diagnostic software + exclusive cloud service

or:

AI diagnostic software + affiliated specialist network.

Potential issues include:

• tying;
• bundling;
• loyalty discounts;
• contractual exclusivity;
• technical tying;
• default settings;
• preferential ranking.

The competitive question is whether the conduct forecloses rival providers rather than merely offering an integrated product.

8. Self-Preferencing

Suppose an AI diagnostic platform simultaneously operates:

1. the diagnostic engine;
2. the specialist marketplace; and
3. a network of affiliated specialists.

The AI system could theoretically recommend its affiliated specialists more frequently.

For example:

Patient asks for second opinion → AI generates list of specialists → affiliated specialists appear first → independent specialists receive fewer referrals.

Potential competition concerns include:

• discriminatory ranking;
• preferential access;
• manipulation of referral algorithms;
• exclusion of competing specialists;
• leveraging diagnostic market power into specialist services.

The same conceptual problem can arise in digital-platform cases where the platform controls both the infrastructure and a downstream service.

9. Algorithmic Referral Foreclosure

AI systems may automate referrals based upon supposedly neutral criteria.

However, the algorithm may incorporate:

• ownership relationships;
• contractual relationships;
• preferred-provider status;
• platform participation;
• historical referral data;
• reimbursement arrangements.

This creates a risk of algorithmic foreclosure.

The important legal question is not simply:

“Is the algorithm biased?”

It is:

“Does the algorithm use market power in one market to exclude or disadvantage competitors in another market?”

10. Interoperability Restrictions

Interoperability can be particularly important in medical AI.

A dominant platform might restrict:

• API access;
• EHR integration;
• imaging export;
• structured diagnostic reports;
• patient-consent interfaces;
• laboratory data transfer;
• specialist referral information.

A technically incompatible rival may then be unable to offer a second opinion efficiently.

This can create a switching-cost moat.

The problem becomes stronger when the incumbent's technology becomes a de facto industry standard.

11. Six Important Case Laws

1. IMS Health GmbH & Co. OHG v NDC Health GmbH & Co. KG, Case C-418/01

The Court of Justice considered a refusal to license a copyrighted “brick structure” used for pharmaceutical sales data.

The case is important because it addressed the circumstances in which refusal by a dominant undertaking to provide access to an input may constitute abuse.

The Court emphasized the exceptional nature of compulsory access and developed stringent conditions involving indispensability and the elimination of competition.

Application to AI diagnostics

An AI diagnostic database, interoperability structure or proprietary clinical data architecture should not automatically be treated as an essential facility.

A claimant would need to establish something approaching:

Indispensability → inability to reproduce → foreclosure of effective competition → absence of sufficient justification.

Thus, IMS Health provides an important framework for claims involving refusal to provide access to diagnostic data or infrastructure.

2. Oscar Bronner GmbH & Co. KG v Mediaprint, Case C-7/97

Bronner is a leading European essential-facilities case concerning access to infrastructure controlled by another undertaking.

The Court adopted a demanding standard for compelling access, particularly where the infrastructure was developed through investment by the dominant undertaking and alternatives might exist.

Application to AI diagnostics

Consider an incumbent that has developed:

• a massive diagnostic database;
• AI infrastructure;
• cloud-based diagnostic architecture; and
• proprietary clinical workflow.

A competitor seeking mandatory access cannot simply argue:

“The incumbent has something valuable, therefore it must share it.”

The Bronner principle requires careful examination of indispensability and realistic alternatives.

This is particularly important where competitors could construct alternative datasets or use other imaging, laboratory or EHR sources.

3. United States v Microsoft Corp.

The Microsoft litigation is important for AI diagnostic ecosystems because it demonstrates how control over a technological platform can have consequences for adjacent markets.

The final judgment contained extensive interoperability provisions requiring Microsoft to facilitate interoperability with Windows and provide qualified parties with access to relevant technical information.

Application to AI diagnostics

The analogy is significant where:

AI diagnostic platform → operating/workflow layer → competing applications

If the dominant diagnostic ecosystem controls the technical interface through which competing diagnostic applications function, interoperability restrictions could potentially become an important competitive issue.

The key lesson is that technical architecture itself can become a competitive bottleneck.

4. FTC v. St. Luke's Health System Ltd.

This healthcare merger involved St. Luke's acquisition of Saltzer Medical Group.

The FTC and Idaho challenged the transaction on the ground that it would substantially increase concentration in adult primary-care physician services. The district court found a violation of Section 7 of the Clayton Act and ordered divestiture; the Ninth Circuit affirmed.

The FTC alleged that the combination would give St. Luke's approximately 60% of the adult PCP market in Nampa.

Application to AI diagnostic ecosystems

The case demonstrates the importance of examining ecosystem consolidation rather than individual products in isolation.

An AI company acquiring:

• diagnostic providers;
• specialist networks;
• hospitals;
• referral platforms; or
• physician groups

could potentially create competitive concerns if the acquisitions eliminate important independent alternatives.

AI therefore does not remove traditional merger-control analysis.

5. FTC v. Phoebe Putney Health System, 568 U.S. 216 (2013)

The Supreme Court considered the acquisition of Palmyra Park Hospital by a hospital authority associated with Phoebe Putney.

The FTC alleged that the transaction would substantially reduce competition in acute-care hospital services. The Supreme Court held that the state-action doctrine did not immunize the acquisition from federal antitrust scrutiny.

Application to AI diagnostic ecosystems

The case is relevant to ecosystem consolidation and institutional bottlenecks.

An AI diagnostic provider may seek to acquire or integrate with:

• hospitals;
• laboratories;
• imaging centers;
• specialist networks;
• telehealth platforms.

Competition authorities may therefore examine whether successive acquisitions eliminate independent competitive alternatives and permit the ecosystem to control multiple stages of healthcare delivery.

6. Omni Healthcare Inc. v. Health First, Inc.

This U.S. healthcare antitrust litigation involved allegations concerning exclusive referral arrangements, provider-network exclusion and vertical integration across interconnected healthcare markets.

The allegations included exclusive referral practices and exclusion of independent physicians from networks, with the plaintiffs asserting that these practices reinforced Health First's position across hospital, physician, ancillary-service and insurance markets.

Application to AI diagnostic systems

This is especially relevant to second-opinion dependency.

Imagine:

AI diagnostic platform → affiliated hospital → affiliated specialist → affiliated second-opinion provider

If independent physicians who refuse to participate are excluded from the platform's referral ecosystem, the platform could potentially extend power from diagnostics into specialist services.

The legal analysis would depend on market definition, market power, contractual structure, foreclosure and procompetitive justifications.

12. Additional Healthcare Authority: Smith v Northern Michigan Hospitals

In Smith v Northern Michigan Hospitals, the Sixth Circuit considered allegations concerning an emergency-room referral system and an exclusive contract for emergency-room staffing.

The case illustrates how hospital referral arrangements can raise Section 1 questions when coordination among healthcare providers allegedly restricts competition.

For AI systems, the modern equivalent could involve an automated referral mechanism that systematically channels patients toward affiliated providers.

13. Competition Risks in AI Second-Opinion Markets

14. The “Second-Opinion Bottleneck” Model

A useful competition-law framework is:

Stage 1 — Diagnostic dominance

The AI system becomes widely used by hospitals and physicians.

↓

Stage 2 — Data accumulation

The platform accumulates:

• diagnostic images;
• clinical histories;
• physician feedback;
• outcomes;
• specialist reports.

↓

Stage 3 — Workflow integration

Hospitals integrate the platform into their EHR and clinical workflow.

↓

Stage 4 — Referral control

The platform begins recommending specialists and second-opinion providers.

↓

Stage 5 — Network effects

More patients generate more data.

More data improve the AI.

Better AI attracts more hospitals.

More hospitals attract more specialists.

↓

Stage 6 — Dependency

Competing diagnostic providers find it increasingly difficult to obtain:

• patients;
• data;
• referrals;
• interoperability;
• validation opportunities.

↓

Stage 7 — Competitive foreclosure

The original diagnostic platform becomes a healthcare gateway rather than merely a diagnostic tool.

15. Network Effects

AI diagnostics can exhibit several network effects.

Data network effect

More patients → more data → better model → more users.

Physician network effect

More physicians → more referrals → more patients → more physician participation.

Specialist network effect

More specialists → better second-opinion coverage → greater platform attractiveness.

Institutional network effect

More hospitals → more interoperability → greater ecosystem utility.

These effects can produce substantial competitive benefits but may also increase entry barriers once the ecosystem reaches sufficient scale.

16. Switching Costs and Lock-In

Switching from one diagnostic AI provider to another may require:

• retraining physicians;
• converting historical records;
• revalidating models;
• changing APIs;
• replacing hardware;
• rewriting hospital workflows;
• renegotiating contracts;
• retraining administrative staff.

Consequently, a theoretically available competitor may not constitute an effective competitive constraint.

Competition analysis should therefore distinguish between:

Nominal availability and commercially realistic substitutability.

17. Privacy and Competition Are Interconnected

Health data are unusually sensitive.

A competition remedy requiring data sharing cannot simply ignore:

• patient consent;
• confidentiality;
• cybersecurity;
• medical-record legislation;
• data minimization;
• purpose limitation;
• professional secrecy.

Accordingly, an AI platform may have legitimate reasons for restricting access.

This means that a competition authority considering interoperability should distinguish between:

legitimate privacy/security restrictions

and

strategic restrictions designed to exclude competitors.

18. Procompetitive Justifications

AI diagnostic integration can generate genuine efficiencies.

Faster diagnosis

AI can reduce diagnostic turnaround time.

Lower duplication

Shared data can prevent unnecessary repeat testing.

Improved clinical coordination

Primary physicians and specialists can work from the same diagnostic record.

Better second opinions

An integrated platform can actually make independent review easier by making records available to specialists.

Quality improvement

More clinical data may improve model performance.

Safety

Centralized monitoring may allow rapid detection of model failures.

Therefore, competition law should not treat integration itself as harmful.

The relevant inquiry is whether particular conduct produces unjustified foreclosure.

19. Remedies

Where competition concerns are established, possible remedies could include:

1. Interoperability obligations

Require standardized access to diagnostic records or APIs.

2. Data portability

Allow patients and authorized providers to transfer relevant records.

3. Non-discriminatory access

Prevent the platform from selectively favoring affiliated providers.

4. Ranking transparency

Require disclosure or auditing of referral-ranking criteria.

5. Non-exclusivity

Restrict contracts preventing hospitals or physicians from using competing diagnostic systems.

6. Data separation

A regulator may require functional or contractual separation between diagnostic data and downstream commercial operations.

7. Merger remedies

Acquisitions that remove important competitive alternatives may require behavioral or structural remedies depending on the circumstances.

20. Practical Legal Test

For an AI diagnostic ecosystem, the following analytical sequence is useful:

1. Define the relevant market

↓

2. Establish market power

↓

3. Identify the controlled input or gateway

↓

4. Determine whether competitors depend upon it

↓

5. Establish whether realistic alternatives exist

↓

6. Identify exclusionary conduct

↓

7. Measure foreclosure

↓

8. Examine consumer and patient effects

↓

9. Consider privacy/security constraints

↓

10. Evaluate objective and efficiency justifications

↓

11. Assess less restrictive alternatives

↓

12. Determine appropriate remedy

21. Key Legal Principle

The central competition-law issue can be expressed as:

AI diagnostic integration becomes a competition concern when control over diagnostic infrastructure is used to control access to adjacent healthcare markets, particularly where patients or competing providers cannot realistically obtain independent alternatives.

The most important distinction is therefore between:

AI-assisted integration
and
AI-enabled foreclosure.

The former can improve healthcare delivery; the latter may raise issues under abuse-of-dominance, monopolization, tying, exclusive dealing, refusal-to-deal, merger-control and interoperability doctrines.

22. Conclusion

AI diagnostic ecosystems create a distinctive competition problem because diagnosis can become a gateway to the rest of healthcare.

The second-opinion market is particularly sensitive. If one ecosystem controls the initial diagnosis, underlying patient data, referral infrastructure, specialist marketplace and interoperability layer, competitors may become dependent upon the very platform with which they are attempting to compete.

The leading authorities do not establish that AI diagnostic platforms must generally provide their data or infrastructure to competitors. IMS Health and Bronner demonstrate the demanding conditions associated with compulsory access, while Microsoft illustrates the significance of interoperability in technology markets. St. Luke's, Phoebe Putney and Omni Healthcare demonstrate how healthcare consolidation, referral structures and vertical relationships can affect competition.

Accordingly, the strongest legal analysis should focus on indispensability, market power, interoperability, foreclosure, referral control, switching costs, data advantages, network effects and objective justification, rather than treating AI integration itself as unlawful.